203 related articles for article (PubMed ID: 34274564)
1. Detection of EGFR mutations in liquid biopsy samples using allele-specific quantitative PCR: A comparative real-world evaluation of two popular diagnostic systems.
Szpechcinski A; Bryl M; Wojcik P; Czyzewicz G; Wojda E; Rudzinski P; Duk K; Moes-Sosnowska J; Maszkowska-Kopij K; Langfort R; Barinow-Wojewodzki A; Chorostowska-Wynimko J
Adv Med Sci; 2021 Sep; 66(2):336-342. PubMed ID: 34274564
[TBL] [Abstract][Full Text] [Related]
2. Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer.
Kimura H; Ohira T; Uchida O; Matsubayashi J; Shimizu S; Nagao T; Ikeda N; Nishio K
Lung Cancer; 2014 Mar; 83(3):329-33. PubMed ID: 24439568
[TBL] [Abstract][Full Text] [Related]
3. Critical Assessment in Routine Clinical Practice of Liquid Biopsy for EGFR Status Testing in Non-Small-Cell Lung Cancer: A Single-Laboratory Experience (LPCE, Nice, France).
Heeke S; Benzaquen J; Hofman V; Ilié M; Allegra M; Long-Mira E; Lassalle S; Tanga V; Salacroup C; Bonnetaud C; Fayada J; Gazoppi L; Ribeyre L; Castelnau O; Garnier G; Cattet F; Nanni I; de Fraipont F; Cohen C; Berthet JP; Leroy S; Poudenx M; Marquette CH; Denis MG; Barlesi F; Hofman P
Clin Lung Cancer; 2020 Jan; 21(1):56-65.e8. PubMed ID: 31519454
[TBL] [Abstract][Full Text] [Related]
4. A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens.
Asaka S; Yoshizawa A; Matsuda K; Yamaguchi A; Yamamoto H; Shiina T; Nakata R; Ogawa K; Zhang M; Honda T
Oncol Rep; 2017 Feb; 37(2):1020-1026. PubMed ID: 27922678
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
[TBL] [Abstract][Full Text] [Related]
6. Application of liquid biopsy-based targeted capture sequencing analysis to improve the precision treatment of non-small cell lung cancer by tyrosine kinase inhibitors.
Zhang L; Coffin J; Formenti K; Chu Q; Izevbaye I
BMJ Open Respir Res; 2022 Jan; 9(1):. PubMed ID: 35091437
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of molecular methods for plasma detection of EGFR mutations in non-small cell lung cancer.
Lee K; Lim S; Lee YG; Kim H; Lee S; Yu HJ; Park H; Kwon MJ; Woo HY
Asia Pac J Clin Oncol; 2022 Dec; 18(6):595-604. PubMed ID: 35098673
[TBL] [Abstract][Full Text] [Related]
8. EGFR T790M Mutation Detection in Patients With Non-Small Cell Lung Cancer After First Line EGFR TKI Therapy: Summary of Results in a Three-Year Period and a Comparison of Commercially Available Detection Kits.
Bencze E; Bogos K; Kohánka A; Báthory-Fülöp L; Sárosi V; Csernák E; Bittner N; Melegh Z; Tóth E
Pathol Oncol Res; 2022; 28():1610607. PubMed ID: 36277960
[No Abstract] [Full Text] [Related]
9. Evaluation of PCR-HRM, RFLP, and direct sequencing as simple and cost-effective methods to detect common EGFR mutations in plasma cell-free DNA of non-small cell lung cancer patients.
Zaini J; Syahruddin E; Yunus M; Andarini SL; Hudoyo A; Masykura N; Yasril R; Ridwanuloh A; Hidajat H; Nurwidya F; Suharsono S; Utomo ARH
Cancer Rep (Hoboken); 2019 Aug; 2(4):e1159. PubMed ID: 32721094
[TBL] [Abstract][Full Text] [Related]
10. Clinical influence of switching companion diagnostic tests for EGFR-TKs from Therascreen to Cobas v2.
Uchibori K; Takano N; Manabe R; Tsugitomi R; Ogusu S; Tozuka T; Sakamoto H; Yoshida H; Amino Y; Ariyasu R; Kitazono S; Yanagitani N; Nishio M
Thorac Cancer; 2021 Mar; 12(6):906-913. PubMed ID: 33528892
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of liquid biopsy for EGFR driver, T790M mutation and EGFR amplification in plasma in patients with acquired resistance to afatinib.
Oya Y; Yoshida T; Asada K; Oguri T; Inui N; Morikawa S; Ito K; Kimura T; Kunii E; Matsui T; Kubo A; Kato T; Abe T; Tsuda T; Hida T
BMC Cancer; 2021 Jan; 21(1):57. PubMed ID: 33435905
[TBL] [Abstract][Full Text] [Related]
12. Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.
Hsiue EH; Lee JH; Lin CC; Yang JC
Expert Rev Mol Diagn; 2016 Dec; 16(12):1251-1257. PubMed ID: 27737606
[TBL] [Abstract][Full Text] [Related]
13. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
[TBL] [Abstract][Full Text] [Related]
14. Real-World Data of the Correlation between EGFR Determination by Liquid Biopsy in Non-squamous Non-small Cell Lung Cancer (NSCLC) and the EGFR Profile in Tumor Biopsy.
Soria-Comes T; Palomar-Abril V; Ureste MM; Guerola MT; Maiques ICM
Pathol Oncol Res; 2020 Apr; 26(2):845-851. PubMed ID: 30847713
[TBL] [Abstract][Full Text] [Related]
15. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.
Yang Y; Shen X; Li R; Shen J; Zhang H; Yu L; Liu B; Wang L
Oncotarget; 2017 Jul; 8(30):49773-49782. PubMed ID: 28572536
[TBL] [Abstract][Full Text] [Related]
16. Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer.
Lee KWC; Li MSC; Gai W; Lau YM; Chan AKC; Chan OSH; Lee CK; Yeung RMW; Fung SYH; Cheung WF; Chan VW; Leung L; Kam KNP; Mok TSK
JAMA Oncol; 2023 Feb; 9(2):261-265. PubMed ID: 36580285
[TBL] [Abstract][Full Text] [Related]
17. Comparison of plasma ctDNA and tissue/cytology-based techniques for the detection of EGFR mutation status in advanced NSCLC: Spanish data subset from ASSESS.
Arriola E; Paredes-Lario A; García-Gomez R; Diz-Tain P; Constenla M; García-Girón C; Márquez G; Reck M; López-Vivanco G
Clin Transl Oncol; 2018 Oct; 20(10):1261-1267. PubMed ID: 29623586
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of 2 real-time PCR assays for in vitro diagnostic use in the rapid and multiplex detection of EGFR gene mutations in NSCLC.
Wong AT; To RM; Wong CL; Chan WK; Ma ES
Diagn Mol Pathol; 2013 Sep; 22(3):138-43. PubMed ID: 23846439
[TBL] [Abstract][Full Text] [Related]
19. A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer.
Torres S; González Á; Cunquero Tomas AJ; Calabuig Fariñas S; Ferrero M; Mirda D; Sirera R; Jantus-Lewintre E; Camps C
Expert Rev Mol Diagn; 2020 Jun; 20(6):575-582. PubMed ID: 32011193
[TBL] [Abstract][Full Text] [Related]
20. Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study.
Kogo M; Fujimoto D; Hosoya K; Nagata K; Nakagawa A; Tachikawa R; Yamashita D; Kitamura Y; Imai Y; Tomii K
BMC Cancer; 2020 Feb; 20(1):104. PubMed ID: 32028905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
